mRNA Vaccine Development Services for SARS-CoV-2

With our extensive experience and advanced platform, Creative Biolabs are therefore confident in offering the best vaccine development services for different types of diseases caused by viruses from coronaviridae family, including the novel coronavirus (SARS-CoV-2). In response to the currently raging SARS-CoV-2, we are actively conducting research and have proposed strategies for the development of mRNA vaccines, hoping to contribute a little bit to this epidemic.

Introduction of mRNA Vaccine

mRNA is the messenger of gene expression: DNA carrying human genetic information is transcribed in the nucleus and produces mRNA, which is then translated in the cytoplasm and produces proteins that perform various physiological functions. Compared with traditional vaccines, mRNA vaccines have subversive advantages in terms of immunogenicity, safety and industrial production. This is because the mRNA vaccine synthesizes antigen mRNA in vitro and then delivers it to the body, which is translated into antigen protein by the cells in vivo. This artificially designed nucleic acid material does not induce the immune response in the human body. More importantly, unlike the stable DNA, the functional mRNA will be degraded without causing other toxicities or side effects to the human body. Therefore, mRNA vaccines have the potential to be quick-manufactured and to become powerful tools against infectious disease.

Fig.1 The mechanisms of DNA and mRNA vaccines. (Li, 2019)

mRNA Vaccine Development Services for SARS-CoV-2

The SARS-CoV-2 is a member of β-coronavirus genus and carries a single positive RNA genome of 30 kilobases. Coronavirus transcription involves a discontinuous RNA synthesis (template switch) during the extension of negative copies of subgenomic mRNAs. Based on the understanding of coronaviruses, using our unique vaccine development platform technology, Creative Biolabs has the ability to quickly synthesize mRNAs of multiple different antigen sequences against key targets of SARS-CoV-2, and obtain effective antigens through screening to develop mRNA vaccines. Our mRNA vaccine development advantages are:

• Short production cycle - RNA synthesis in vitro without protein synthesis
• Safety - does not insert gene mutations and can be degraded by normal cells
• Efficient drug loading technology - ensuring the safety and effectiveness of mRNA delivery
• Easy to achieve standardized production - once RNA sequences are identified, cells can be turned into small pharmaceutical factories

In recent years, RNA sequence engineering technology has made synthetic mRNAs have better translation function than previous, and highly efficient and low-toxic vectors can significantly improve the expression of antigens in vivo. As a member of the field of viral vaccine development, our mRNA vaccine platform has made great progress in immunogenicity and efficacy. If you are interested in our services, please contact us for more details.

Reference

1. Li, J., et al. Advances in mRNA vaccines for infectious diseases. Frontiers in Immunology. 2019, 10: 594.

For Research Use Only. We do not provide direct services or products for patients.